Athenex Inc Quick Ratio (ATNX) starting from the fourth quarter 2022 to fourth quarter 2021, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Athenex Inc   (NASDAQ: ATNX)

Athenex Inc 's Quick Ratio

ATNX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2022, Quick Ratio fell to 0.27 below Athenex Inc average.

Within Major Pharmaceutical Preparations industry 360 other companies have achieved higher Quick Ratio than Athenex Inc in fourth quarter 2022. While Quick Ratio total ranking has improved so far during the Q4 2022 to 2452, from total ranking in the third quarter 2022 at 2791.

Explain Quick Ratio?
How much Cash & cash equivalents ATNX´s has?
What are ATNX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ATNX Quick Ratio (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2		 (Mar 31 2022)
Q1		 (Dec 31 2021)
Q4
Y / Y Current Liabilities Change 19.18 % 17.57 % 47.3 % 68.11 % 55.34 %
Y / Y Cash & cash equivalent Change -30.61 % -59.08 % -82.09 % -78.12 % -78.19 %
Quick Ratio MRQ 0.27 0.44 0.26 0.48 0.47
ATNX's Total Ranking # 2452 # 2791 # 3776 # 3097 # 3075
Seq. Current Liabilities Change 38.61 % -5.92 % 12.59 % -18.83 % 36.74 %
Seq. Cash & cash equivalent Change -13.01 % 55.27 % -37.72 % -17.51 % -48.7 %



Quick Ratio fourth quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 361
Healthcare Sector # 708
Overall Market # 2452


Quick Ratio Statistics
High Average Low
3.68 1.77 0.26
(Mar 31 2021)   (Jun 30 2022)




Financial Statements
Athenex Inc 's Current Liabilities $ 115 Millions Visit ATNX's Balance sheet
Athenex Inc 's Cash & cash equivalent $ 32 Millions Visit ATNX's Balance sheet
Source of ATNX's Sales Visit ATNX's Sales by Geography


Cumulative Athenex Inc 's Quick Ratio

ATNX's Quick Ratio for the trailling 12 Months

ATNX Quick Ratio

 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months		 (Dec 31 2021)
12 Months
Y / Y Current Liabilities TTM Growth 33.26 % 44.67 % 43.48 % 28.86 % 3.45 %
Y / Y Cash & cash equivalent TTM Growth -70.48 % -76.19 % -73.61 % -58.34 % -34.69 %
Quick Ratio TTM 0.35 0.41 0.58 0.99 1.59
Total Ranking TTM # 4843 # 4833 # 4791 # 2270 # 4716
Seq. Current Liabilities TTM Growth 5.35 % 3.72 % 9.28 % 11.6 % 14.37 %
Seq. Cash & cash equivalent TTM Growth -9.76 % -26.86 % -35.44 % -30.72 % -27.22 %

Quick ratio ranking by company, industry and sector >> Back to ATNX Financial Strength Comparisons >> Go to Compare ATNX Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q4 2022 to $114.88 millions, cumulative Quick Ratio decreased to 0.35 below the Athenex Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 599 other companies have achieved higher Quick Ratio than Athenex Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2022 from 4833 to 4843.

Explain Quick Ratio?
How much Cash & cash equivalents ATNX´s has?
What are ATNX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 600
Healthcare Sector # 1211
Within the Market # 4843


trailing twelve months Quick Ratio Statistics
High Average Low
2.63 1.63 0.35
(Jun 30 2021)   (Dec 31 2022)




Companies with similar Quick Ratio in the quarter ending Dec 31 2022, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2022 MRQ Cash & cash equivalentDec 31 2022 MRQ Current Liabilities
Ibio inc   0.75 $ 22.705  Millions$ 30.436  Millions
Intercure Ltd   0.74 $ 232.589  Millions$ 312.719  Millions
Zyversa Therapeutics Inc   0.73 $ 5.949  Millions$ 8.186  Millions
Precigen Inc   0.71 $ 55.953  Millions$ 78.645  Millions
One World Products Inc   0.70 $ 1.461  Millions$ 2.088  Millions
Cumberland Pharmaceuticals Inc   0.70 $ 19.758  Millions$ 28.407  Millions
Oncorus Inc   0.69 $ 25.709  Millions$ 37.207  Millions
Societal Cdmo Inc   0.69 $ 14.995  Millions$ 21.729  Millions
Avid Bioservices Inc   0.69 $ 59.916  Millions$ 87.319  Millions
Akebia Therapeutics Inc   0.68 $ 90.466  Millions$ 132.233  Millions
Assertio Holdings inc   0.68 $ 64.941  Millions$ 95.316  Millions
Contrafect Corporation  0.68 $ 13.682  Millions$ 20.169  Millions
Opko Health Inc   0.67 $ 153.191  Millions$ 226.993  Millions
Spectrum Pharmaceuticals Inc   0.67 $ 75.096  Millions$ 111.337  Millions
Indivior Pharmaceuticals Inc   0.67 $ 779.000  Millions$ 1,164.000  Millions
Semnur Pharmaceuticals Inc   0.63 $ 0.820  Millions$ 1.292  Millions
Seelos Therapeutics inc   0.62 $ 15.533  Millions$ 25.158  Millions
Perrigo Company Plc  0.62 $ 600.700  Millions$ 974.500  Millions
Protokinetix Incorporated  0.62 $ 0.026  Millions$ 0.042  Millions
Avalo Therapeutics Inc   0.60 $ 13.187  Millions$ 22.114  Millions
Abbott Laboratories  0.59 $ 10,170.000  Millions$ 17,182.000  Millions
Theratechnologies Inc   0.58 $ 23.856  Millions$ 41.065  Millions
Medicure Inc   0.58 $ 3.720  Millions$ 6.427  Millions
Lftd Partners Inc   0.57 $ 3.556  Millions$ 6.210  Millions
Biophytis Sa  0.57 $ 11.824  Millions$ 20.698  Millions
Johnson and Johnson  0.57 $ 23,519.000  Millions$ 41,385.000  Millions
Checkpoint Therapeutics inc   0.56 $ 12.068  Millions$ 21.603  Millions
Gridai Technologies Corp  0.55 $ 1.363  Millions$ 2.484  Millions
Merck and Co Inc   0.55 $ 13,192.000  Millions$ 24,088.000  Millions
Emergent Biosolutions Inc   0.53 $ 642.600  Millions$ 1,204.200  Millions

Date modified: 2026-09-08T15:10:52+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.